Document:

Letter Agreement

 Exhibit 10.1 
 UNITED STATES DEPARTMENT OF THE TREASURY 
 1500 PENNSYLVANIA AVENUE, NW 
 WASHINGTON, D.C. 20220 
 Dear Ladies and Gentlemen:

 The company set forth on the signature page hereto (the “Company”) intends to issue in a private placement the number of
shares of a series of its preferred stock set forth on Schedule A hereto (the “Preferred Shares”) and a warrant to purchase the number of shares of its common stock set forth on Schedule A hereto (the “Warrant” and,
together with the Preferred Shares, the “Purchased Securities”) and the United States Department of the Treasury (the “Investor”) intends to purchase from the Company the Purchased Securities. 
 The purpose of this letter agreement is to confirm the terms and conditions of the purchase by the Investor of the Purchased Securities. Except to the
extent supplemented or superseded by the terms set forth herein or in the Schedules hereto, the provisions contained in the Securities Purchase Agreement – Standard Terms attached hereto as Exhibit A (the “Securities Purchase
Agreement”) are incorporated by reference herein. Terms that are defined in the Securities Purchase Agreement are used in this letter agreement as so defined. In the event of any inconsistency between this letter agreement and the
Securities Purchase Agreement, the terms of this letter agreement shall govern. 
 Each of the Company and the Investor hereby confirms its
agreement with the other party with respect to the issuance by the Company of the Purchased Securities and the purchase by the Investor of the Purchased Securities pursuant to this letter agreement and the Securities Purchase Agreement on the terms
specified on Schedule A hereto. 
 This letter agreement (including the Schedules hereto) and the Securities Purchase Agreement (including
the Annexes thereto) and the Warrant constitute the entire agreement, and supersede all other prior agreements, understandings, representations and warranties, both written and oral, between the parties, with respect to the subject matter hereof.
This letter agreement constitutes the “Letter Agreement” referred to in the Securities Purchase Agreement. 
 This letter agreement
may be executed in any number of separate counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts will together constitute the same agreement. Executed signature pages to this letter agreement may be
delivered by facsimile and such facsimiles will be deemed as sufficient as if actual signature pages had been delivered. 
 *** 

 In witness whereof, this letter agreement has been duly executed and delivered by the duly authorized
representatives of the parties hereto as of the date written below. 
  

			
	UNITED STATES DEPARTMENT OF THE TREASURY
		
	By:	 	  

	Name:	 	
	Title:	 	

  

			
	 COMPANY: NARA BANCORP, INC.

		
	By:	 	  

	Name:	 	Min Kim
	Title:	 	President and Chief Executive Officer

 Date: 

 EXHIBIT A 
 SECURITIES PURCHASE AGREEMENT 

 SCHEDULE A 
 ADDITIONAL TERMS AND CONDITIONS 
 Company Information: 
 Name of the Company: Nara Bancorp, Inc. 
 Corporate or other organizational form: Corporation 
 Jurisdiction of Organization: Delaware 
 Appropriate Federal Banking Agency: Federal Reserve Board 
  

			
	Notice Information:	  	Nara Bancorp, Inc.
		  	3731 Wilshire Blvd., Suite 1000
		  	Los Angeles, California 90010
		  	 Attention: Alvin D. Kang, Executive Vice President and
 Chief Financial Officer

		  	Facsimile: (213) 235-3033
		
	Copy to:	  	Mayer Brown LLP
		  	350 South Grand Avenue
		  	Los Angeles, California 90071
		  	Attention: James R. Walther, Esq.
		  	Facsimile: (213) 625-0248

 Terms of the Purchase: 
 Series of Preferred Stock Purchased: Fixed Rate Cumulative Perpetual Preferred Stock, Series A 
 Per Share
Liquidation Preference of Preferred Stock: $1,000 
 Number of Shares of Preferred Stock Purchased: 67,000 
 Dividend Payment Dates on the Preferred Stock: February 15, May 15, August 15, and November 15 of each year 
 Number of Initial Warrant Shares: 1,042,531 
 Exercise Price of the Warrant: $9.64 
 Purchase Price: $67,000,000 

 SCHEDULE A 
 Closing: 
 Location of Closing: Telephonic 
 Time and Date of Closing: 8:00AM (PST) on November 21, 2008 
  

			
	Wire Information for Closing:	  	ABA Number: 1220-4172-7
		
		  	Bank: Nara Bank
		  	Account Name: Nara Bancorp, Inc.
		
		  	Account Number: ***********
		  	Beneficiary: Nara Bancorp, Inc.
		
		  	 Attn: Alvin D. Kang, Executive Vice
 President and Chief Financial Officer

 SCHEDULE B 
 CAPITALIZATION 
  

				
	 Capitalization Date:
	  	 	October 31, 2008
		
	Common Stock	  		
		
	 Par value:
	  	$	0.001
		
	 Total Authorized:
	  	 	40,000,000
		
	 Outstanding:
	  	 	26,201,672
		
	 Subject to options, warrants, convertible securities, etc.:
	  	 	1,288,120
		
	 Reserved for benefit plans and other issuances:
	  	 	1,255,800
		
	 Remaining authorized but unissued:
	  	 	13,798,328
		
	 Shares issued after Capitalization Date:
	  	 	0
	 (other than pursuant to warrants, options, convertible securities, etc. as set forth above)
	  		
		
	Preferred Stock	  		
		
	 Par value:
	  	$	0.001
		
	 Total Authorized:
	  	 	10,000,000
		
	 Outstanding (by series):
	  	 	0
		
	 Reserved for issuance:
	  	 	0
		
	 Remaining authorized but unissued:
	  	 	10,000,000

 SCHEDULE C 
 REQUIRED STOCKHOLDER APPROVALS 
  

					
	 	  	Required1	  	% Vote Required
	Warrants — Common Stock Issuance	  		  	
			
	 Charter Amendment
	  		  	
			
	 Stock Exchange Rules
	  		  	

 If no stockholder approvals are required, please so indicate by checking the box:  x. 
  

	1	If stockholder approval is required, indicate applicable class/series of capital stock that are required to vote. 

 SCHEDULE D 
 LITIGATION 
 List any exceptions to the representation and warranty in Section 2.2(l) of the Securities
Purchase Agreement – Standard Terms. 
 The Company is a nominal defendant in a shareholder derivative lawsuit which purports to be
brought on the Company’s behalf by Dr. Thomas Chung, a former chairman of the Company’s board of directors (the “Chung Lawsuit”) which was filed on May 20, 2008 in the Superior Court of California, County of Los
Angeles. The Chung Lawsuit alleges that the members of the Company’s board of directors as composed on the date the lawsuit was filed, as well as the Company board as it was composed in March 2005 (collectively, the “Boards”) breached
their fiduciary duties to the Company’s shareholders and mismanaged corporate assets. In addition, the Chung Lawsuit names Mr. Chong-Moon Lee, also a former Chairman of the Company’s board of directors as a defendant and alleges that
Mr. Lee violated insider trading laws and wasted corporate assets. 
 The Chung Lawsuit alleges that the 2005 restatement of the
Company’s 2002 financial statements was not required and was undertaken by the Board as composed in 2005 in bad faith. Dr. Chung further alleges that the restatement resulted in a decline of $54 million in the value of the Company’s
outstanding stock, that Mr. Lee was aware (and the public was not) that the restatement was improper and that the Company’s stock price was therefore artificially low, at the time he subsequently purchased 1.4 million shares of common
stock from the Company in 2005, and that the Board as composed in 2008 breached its fiduciary duties by failing to pursue the claims alleged in the Chung Lawsuit. Dr. Chung also alleges, among other things, that the Board as composed in 2008
breached its fiduciary duties by failing to pursue claims against the Company’s auditors, Crowe Chizek & Company, the law firm that advised the Company in connection with the restatement, Fulbright & Jaworski, and the
consulting firm who advised the Company and its counsel in connection with the restatement, Navigant Consultants. The letter between Dr. Chung and Mr. Hong, the restatement of the Company’s 2002 financial statements and certain
related matters are further described in the form 8-K/A filed March 31, 2005. 
 The complaint alleges damages exceeding $54 million
from the Boards and $7.168 million from Mr. Lee, together with reimbursement from all defendants of his legal costs incurred in pursuing the Chung Lawsuit. If any damages are ever recovered by the purported shareholder derivative lawsuit, such
damages, but not any awards of legal costs, would be payable to the Company. 
 The Company filed a demurrer with the Superior Court
seeking to dismiss the Chung Lawsuit for failure to state a cause of action on which relief may be based on July 9, 2008. Oral argument on the demurrer is currently scheduled to be heard by the court on December 22, 2008. The
Company believes the Chung Lawsuit is without merit. 
 If none, please so indicate by checking the box:   ̈.

 SCHEDULE E 
 COMPLIANCE WITH LAWS 
 List any exceptions to the representation and warranty in the second sentence of
Section 2.2(m) of the Securities Purchase Agreement – Standard Terms. 
 If none, please so indicate by checking the
box:  x. 
 List any exceptions to the representation and warranty in the last sentence of Section 2.2(m)
of the Securities Purchase Agreement – Standard Terms. 
 If none, please so indicate by checking the box:  x. 

 SCHEDULE F 
 REGULATORY AGREEMENTS 
 List any exceptions to the representation and warranty in Section 2.2(s) of the
Securities Purchase Agreement – Standard Terms. 
 On July 29, 2005, the Federal Reserve Bank of San Francisco (the “Reserve
Bank”) and the California Department of Financial Institutions (together with the Reserve Bank, the “Regulatory Agencies”) entered into a Memorandum of Understanding (the “MOU”) with Nara Bank. The MOU required that Nara
Bank take steps to strengthen management, board oversight and internal controls. Upon review of Nara Bank’s compliance with the requirements of the MOU, the Regulatory Agencies terminated the MOU by letter dated July 12, 2007. 

If none, please so indicate by checking the box:   ̈.Stock Purchase Agreement

 Exhibit 10.1 
 STOCK PURCHASE AGREEMENT 
 BETWEEN 
 ARROWHEAD RESEARCH 
 AND 
 TEGO BIOSCIENCES 
 Dated as of the date
indicated on the signature page hereto 

 STOCK PURCHASE AGREEMENT 
 THIS STOCK PURCHASE AGREEMENT (“Agreement”) is made as of the date indicated on the later of the dates indicated on the signature
pages hereto, by and between Arrowhead Research Corporation (the “Seller”), a Delaware corporation, and Tego Biosciences, Inc. (the “Purchaser”). 
 RECITALS 
 WHEREAS, Seller
currently owns 5,000,000 shares of Series A-1 Preferred Stock (the “Preferred Shares”) of Tego Biosciences, Inc. (the “Company”); 
 WHEREAS, the Purchaser wishes to purchase from the Seller, and the Seller wishes to sell to the Purchaser the Preferred Shares at $.34 per share, on the
terms and conditions set forth herein. 
 NOW THEREFORE, in consideration of the premises and mutual agreements herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
 ARTICLE 1 
 Sale and Purchase of Shares 
 1.1 Sale of Shares. Subject to the terms and conditions of this Agreement, the Seller will sell to the Purchaser, and the Purchaser will purchase,
5,000,000 Preferred Shares at $.34 per share. The Purchaser shall pay to the Seller, by means of wire transfer, representing immediately available funds, an amount equal to $1,700,000. 
 1.2 Closing Date. The sale of Preferred Shares contemplated hereby (the “Share Sale”) will close on November 21 2008
(the “Closing Date”). 
 ARTICLE 2 
 Representations and Warranties of the Seller 
 In order to induce the Purchaser
to enter into this Agreement and consummate the transactions contemplated hereby, Seller hereby makes to the Purchaser the representations and warranties contained in this ARTICLE 2, as of the date hereof and of the applicable Closing Date.

 2.1 Good Standing; Power and Authority; Legal and Binding Nature; Compliance with Other Instruments. The Company is duly organized,
validly existing and in good standing under the laws of the State of Delaware. Seller has full power and authority and has taken all required corporate and other action necessary to permit it to execute, deliver and perform all of its obligations
contained in this Agreement, and to issue the Shares hereunder. This Agreement has been duly authorized and validly executed by, and is the valid and binding obligation of, Seller enforceable in accordance with its terms. Neither the execution and
delivery by Seller of this Agreement, nor the performance by Seller of its obligations hereunder, requires the consent, approval or authorization of any person or governmental authority, which consent, approval or authorization has not been
obtained. 
 2.2 Non-Contravention. The execution, delivery and performance of this Agreement does not and will not: (i) conflict
with or result in any default under any material contract, obligation or commitment of Seller or any provision of Seller’s certificate of incorporation or bylaws; (ii) result in the creation of any Lien (as defined below) of any kind, or
the interest of a vendor or lessor under any conditional sale agreement, capitalized lease or other title retention agreement of any nature upon any of the properties or assets of Seller, or (iii) violate any instrument, agreement, judgment,
decree or order, or any statute, 

  

 1 

 
rule or regulation of any federal, state or local government or agency, applicable to Seller or to which Seller is a party, except in each case for such
conflicts, defaults, Liens or violations that shall not have a material adverse effect on Seller. “Liens” means all liens, claims, options, charges, pledges, security interests, voting agreements, trusts, encumbrances,
rights, mortgages or restrictions of any nature. 
 ARTICLE 3 
 Representation and Warranties of the Purchaser 
 As a material inducement to the
Seller to enter into this Agreement and consummate the transactions contemplated hereby, Purchaser hereby represents and warrants as of the date hereof to the Company as follows: 
 3.1 Acquisition of Shares. This Agreement is made with Purchaser in reliance upon Purchaser’s representation to the Seller, which by
Purchaser’s execution of this Agreement Purchaser hereby confirms, that the Shares to be received by Purchaser will be acquired for investment for Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or
distribution of any part thereof, and that Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. 
 3.2 No Registration. Purchaser understands and acknowledges that the Shares will not be registered under the Securities Act or under any other applicable blue sky or state securities law, on the grounds that
the sale of the Shares from Seller to Purchaser contemplated by this Agreement is exempt from registration pursuant to Section 4(2) of the Securities Act and the regulations thereunder and are exempt from qualification pursuant to comparable
available exceptions in various states, and that the Seller’s reliance upon such exemptions is predicated upon Purchaser’s representations set forth in this Agreement. Purchaser acknowledges and understands that the Shares (including the
Common Shares into which the Preferred Shares may convert) must be held indefinitely unless the Shares (including the Common Shares into which the Preferred Shares may convert) are subsequently registered under the Securities Act and other
applicable blue sky and state securities laws or an exemption from such registration is available. 
 3.3 Consents and Approvals. No
consent, approval or authorization of, or declaration, filing or registration with, or payment of any tax, fee, fine or penalty to, any governmental or regulatory authority (domestic or foreign) or any other person (either governmental or private),
is required to be obtained or made by Purchaser in connection with the execution and delivery by Purchaser of this Agreement or the consummation by Purchaser of the transactions contemplated hereby. 
 3.4 Investment Representations. Purchaser (a) has such knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of Purchaser’s prospective investment hereunder; (b) has the ability to bear the economic risks of Purchaser’s prospective investment, including a complete loss of the investment; (c) has been
furnished with and has had access to such information as Purchaser has considered necessary to make a determination as to its investment hereunder; (d) has had all questions which have been asked by Purchaser satisfactorily answered by the
Company; (e) has not been offered the Shares by any form of general solicitation or general advertising, including any advertisement, article, notice or other communication published in any newspaper, magazine, or similar media or broadcast
over television or radio, or any seminar or meeting whose attendees have been invited by any general solicitation or general advertising; and (f) has not relied on any representations and warranties of the Company other than those contained in
this Agreement. 
 3.5 Accredited Investor Status. Purchaser is an “accredited investor” within the meaning of Rule 501(a)
of Regulation D promulgated by the SEC under the Securities Act and is an “institutional investor” within the meaning of applicable state statutes and the regulations thereunder. 
  

 2 

 3.6 Restrictions on Transfer. Purchaser understands that unless and until the Company
(i) registers the Shares (including the common shares into which the Preferred Shares may convert) with the SEC pursuant to Section 12, (ii) becomes subject to Section 15(d) of the Exchange Act, (iii) supplies information
pursuant to Rule 15c2 11 thereunder, or (iv) if a registration statement covering the Shares (or a filing pursuant to the exemption from registration under Regulation A of the Securities Act covering the Shares) under the Securities Act is in
effect when Purchaser desires to sell Shares, Purchaser may be required to hold the Shares for an indeterminate period. Purchaser also understands that any sale of the Shares that might be made by Purchaser in reliance upon Rule 144 or Rule 144A
under the Securities Act may be made only in limited amounts in accordance with the terms and conditions of those rules. Purchaser understands and acknowledges that all certificates representing the Shares (as well as the common stock into which the
Preferred Shares may be converted), shall bear the following legend (and any other legend that may be required under any Federal or state securities law), until such Shares are registered under the securities Act, exchanged for securities registered
under the securities Act, or until the holder of the Shares delivers an opinion of its legal counsel, reasonably acceptable to the Company, that such legend is no longer necessary. 
 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 NOR REGISTERED OR QUALIFIED UNDER ANY STATE
SECURITIES LAWS. SUCH SHARES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED, OR HYPOTHECATED UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION IS NOT REQUIRED. ANY TRANSFER OF THE SHARES REPRESENTED BY THIS CERTIFICATE IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE SET FORTH HEREIN.” 

3.7 Authorization. Purchaser has full power and authority to enter into this Agreement and to perform its obligations hereunder and thereunder
and to consummate the transactions contemplated hereby. This Agreement is a valid and binding agreement of Purchaser, enforceable in accordance with its terms. 
 3.8 ERISA. Purchaser will not acquire the Shares with the assets of any “employee benefit plan” as defined in ERISA and no “prohibited transactions” under ERISA and the Code will occur in
connection with the Purchaser’s acquisition of the Shares. 
 3.9 Taxes. Purchaser (a) understands that there may be tax
consequences resulting from the purchase, ownership and/or sale of Shares, and (b) represents and warrants that (i) Purchaser has had a full opportunity to seek the advice of independent counsel respecting this investment and the tax risks
and implications thereof, (ii) Purchaser has relied only upon such independent tax advice and not upon any tax counsel from, or discussions with, Seller or the Company or their respective representatives, and (iii) has never been notified
by the Internal Revenue Service that Purchaser is subject to 20% backup withholding. 
 ARTICLE 4 
 Closing Conditions and Deliveries 
 4.1 Conditions to Purchaser Obligations. The obligation of Purchaser to purchase the Shares and to perform the obligations set forth herein, at the Closing, is subject to the fulfillment on or prior to the Closing Date of the
following conditions, any of which may be waived in accordance with the provisions set forth herein: 
 4.1.1 Delivery of this Agreement
and Shares. The Purchaser shall have received a duly executed copy of this Agreement from Seller. 
  

 3 

 4.1.2 Seller shall have delivered to Purchaser an executed amendment to the Investors’ Rights
Agreement signed by Seller and the other necessary parties, attached as Exhibit A hereto. 
 4.1.3 Accuracy of
Representations and Warranties; Performance of Obligations. The representations and warranties made by Seller herein shall be true and correct on the Closing Date; and Seller shall have performed all obligations and conditions herein required to
be performed or observed by it on or prior to the Closing Date. 
 4.1.4 Absence or Violation or Litigation. The consummation of the
transactions contemplated hereby shall not be in violation of any law or regulation applicable to the Company or Seller. Neither the Company nor Seller shall be subject to any injunction, stay or restraining order nor shall it require any filings,
approvals or consents that have not been previously made or obtained. 
 4.1.5 All Proceedings Satisfactory. All organizational and
other proceedings taken by Seller in connection with the Share Sale, and all documents and instruments related thereto, shall be reasonably satisfactory in form and substance to Purchaser and Purchaser shall have received copies thereof and other
materials (certified, if requested) as Purchaser may reasonably request in connection herewith. 
 4.1.6 Consents and Waivers. Seller
shall have made all filings with, and provided notices to, governmental authorities, regulatory agencies and other entities required to be made by Seller in connection with the execution and delivery of this Agreement, the performance of the Share
Sale and the continued operation of the business of the Company and Seller subsequent to the date hereof. 
 4.2 Conditions to
Seller’s Obligations. Seller’s obligation to sell the Shares and to perform the obligations set forth herein, at the Closing, is subject to the fulfillment on or prior to the Closing Date of the following conditions, any of which may
be waived by Seller (unless specifically stated below) as to any one or more of the Purchasers if such waiver will not adversely affect the other Purchasers: 
 4.2.1 Representations and Warranties Correct. The representations and warranties made by Purchaser herein shall be true and correct on the Closing Date; and Purchaser shall have performed all obligations and
conditions herein required to be performed or observed by it on or prior to the Closing Date. 
 4.2.2 Payments by Purchasers. Seller
shall have received Purchaser’s payment for the number of Shares set forth opposite Purchaser’s name on the signature page hereto. 
 ARTICLE 5 
 Miscellaneous 
 5.1 Delivery of Shares. Seller shall deliver duly issued, non-assessable and fully-executed Shares, free and clear of any and all Liens within thirty (30) days of the Closing Date. 
 5.2 Fiduciary Capacity. If the undersigned is purchasing the Shares in a fiduciary capacity, the above representations and warranties shall be
deemed to have been made on behalf of the person or persons for whom the undersigned is so purchasing. 
  

 4 

 5.3 Entire Agreement. This Agreement, and the agreements referred to herein constitute the full
and entire understanding and agreement among the parties with regard to the subject matter hereof and thereof and supercede all prior written or oral agreements and all contemporaneous oral agreements with respect to the subject matter hereof.

 5.4 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for convenience of reference only and
are not to be considered in construing this Agreement. 
 5.5 Construction of Agreement. None of the parties hereto or their
respective counsel shall be deemed to have drafted this Agreement for purposes of construing the terms hereof. The language in all parts of this Agreement shall in all cases be construed according to its fair meaning, and not strictly for or against
any party hereto. Throughout this Agreement, as the context may require, references to any word used in one tense or case shall include all other appropriate tenses or cases. In addition, unless followed by the word “only”, the term
“including” means “including but not limited to.” 
 5.6 Governing Law. This Agreement is only for the benefit of
the Company and will be construed in accordance with and governed by the laws of the State of Delaware, without giving effect to the conflicts of law provisions thereof. 
 5.7 Attorneys’ Fees. In any dispute between the parties hereto concerning any provision of this Agreement or the rights and duties of any person or entity hereunder, the party or parties prevailing in such
dispute shall be entitled, in addition to such other relief as may be granted, to the attorneys’ fees and court costs incurred by reason of such dispute. 
 5.8 Waivers Strictly Construed. With regard to any power, remedy or right provided herein or otherwise available to any party hereunder (i) no waiver or extension of time shall be effective unless
expressly contained in a writing signed by the waiving party; and (ii) no alteration, modification or impairment shall be implied by reason of any previous waiver, extension of time, delay or omission in exercise, or by any other indulgence.

 5.9 Additional Acts. The parties signatory to this Agreement agree to execute any and all further documents and writings and
perform such other reasonable actions which may be or become necessary or expedient to effectuate and carry out the business of the Company (which shall not include any obligation to make payments), including making commercially reasonable efforts
to provide, post-funding, all information reasonably requested to apply for any and all licenses required for the Company to operate and/or effect any transaction for the purpose of acquiring any licenses for the Company to conduct business.

 5.10 Notices. All notices and other communications required or permitted hereunder shall be effective upon receipt and shall be in
writing and delivered personally, by facsimile transmission, by overnight delivery service or by mail, postage prepaid, addressed (a) if to Purchaser, at Purchaser’s address set forth below its name on the signature pages hereto, or at
such other address as Purchaser shall have furnished to the Company in writing, or (b) if to Unidym, at Unidym, 1430 O’Brien Drive, Suite G, Menlo Park, CA 94025. 
 5.11 Severability; Counterparts. In case any provision of this Agreement shall be invalid, illegal or unenforceable, the validity, legality and
enforceability of the remaining provisions of this Agreement shall not in any way be affected or impaired thereby. This Agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall
constitute one instrument. 
 [PLEASE COMPLETE THE FOLLOWING PAGE] 
  

 5 

 YOU MUST COMPLETE THIS PAGE 
 5.12 Nature of Investor. PLEASE MARK (ONLY ONE BOX NEEDS TO BE CHECKED; CONTACT THE SELLER IF NONE IS APPLICABLE): 
  

	 ̈	A natural person whose net worth (or joint net worth with my spouse) is in excess of $1,000,000 as of the date hereof. 

  

	 ̈	A natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s spouse in excess of $300,000 in each
of those years and has a reasonable expectation of reaching the same income level in the current year. 

  

	 ̈	A trust with total assets in excess of $5,000,000, not formed for the specific purpose of investing in the Interest, whose purchases are directed by a “sophisticated
person” as described in Rule 506(b)(2)(ii) of the Act. 

  

	 ̈	A “bank,” “savings and loan association,” or “insurance company” as defined in the Act. 

  

	 ̈	An “employee benefit plan” as defined in the Employee Retirement Income Security Act of 1974 (a “Plan”) which has total assets in excess of
$5,000,000. 

  

	 ̈	A Plan whose investment decisions, including the decision to subscribe for the Interest, are made solely by (i) a “plan fiduciary” as defined in the Employee Retirement
Income Security Act of 1974, which includes a bank, a savings and loan association, an insurance company or a registered investment adviser, or (ii) an “accredited investor” as defined under Rule 501(a) of the Act.

  

	 ̈	A broker/dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934. 

  

	 ̈	A “private business development company” as defined in the Investment Advisers Act of 1940. 

  

	 ̈	An investment company registered under, or a “business development company” as defined in, the Investment Company Act of 1940. 

  

	 ̈	A Small Business Investment Company licensed by the U.S. Small Business Administration under the Small Business Investment Act of 1958. 

  

	 ̈	A plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees
and having total assets in excess of $5,000,000. 

  

	 ̈	Any organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business Trust, or partnership, not formed for the specific
purpose of investing in the Interest and having total assets in excess of $5,000,000. 

  

	 ̈	Any entity in which all of the equity owners are “accredited investors.” 

 [REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 
  

 6 

 IN WITNESS WHEREOF, the parties hereto have executed this Stock Purchase Agreement as of November 21,
2008. 
  

									
	Purchaser:	 		 	Seller:
			
	TEGO BIOSCIENCES	 		 	ARROWHEAD RESEARCH
					
	By:	 	 /s/ Thomas Haag
	 		 	By:	 	 /s/ Christopher Anzalone

	Name:	 	Thomas Haag	 		 	Name:	 	Christopher Anzalone
	Title:	 	Chief Executive Officer	 		 	Title:	 	Chief Executive Officer

  

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}]]